BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Up 30.5% in August

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 49,200 shares, a growth of 30.5% from the August 15th total of 37,700 shares. Based on an average daily trading volume, of 69,800 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BWAY. Tucker Asset Management LLC boosted its stake in shares of BrainsWay by 1,686.9% in the 4th quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock valued at $35,000 after purchasing an additional 5,145 shares in the last quarter. Virtu Financial LLC bought a new position in BrainsWay in the 1st quarter valued at approximately $60,000. Quadrature Capital Ltd bought a new position in BrainsWay in the 4th quarter valued at approximately $70,000. Rhumbline Advisers boosted its position in BrainsWay by 10.3% in the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after buying an additional 1,695 shares in the last quarter. Finally, Perritt Capital Management Inc bought a new stake in shares of BrainsWay during the second quarter worth $121,000. Institutional investors own 30.11% of the company’s stock.

BrainsWay Stock Performance

Shares of NASDAQ BWAY traded up $0.22 during trading hours on Monday, hitting $8.44. 142,860 shares of the stock were exchanged, compared to its average volume of 94,590. The company’s fifty day simple moving average is $7.32 and its two-hundred day simple moving average is $6.30. The company has a market cap of $140.65 million, a PE ratio of -93.78 and a beta of 1.25. BrainsWay has a 1-year low of $3.09 and a 1-year high of $8.60.

BrainsWay (NASDAQ:BWAY) last issued its earnings results on Tuesday, August 6th. The company reported $0.04 earnings per share for the quarter. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. The firm had revenue of $10.01 million for the quarter, compared to the consensus estimate of $9.40 million. During the same quarter last year, the business posted ($0.05) EPS. As a group, sell-side analysts expect that BrainsWay will post 0.06 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of BrainsWay in a research note on Monday. Northland Securities raised their price target on BrainsWay from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.